Meeting NewsVideo

VIDEO: CDK inhibitors, selective estrogen receptor degrader highlight G1 Therapeutics pipeline

CHICAGO — Raj Malik, MD, chief medical officer and senior vice president for research and development at G1 Therapeutics, spoke with HemOnc Today at ASCO Annual Meeting about study results the company presented and the investigational agents in the pipeline.

Malik provided an overview of research into trilaciclib, a cyclin dependent kinase (CDK) 4/6 inhibitor designed to protect patients’ bone marrow from the effects of chemotherapy.

Results showed patients treated with trilaciclib had significantly less incidence and duration of severe neutropenia. They also were less likely to require red blood cell transfusions.

The company expects to file for potential regulatory approval next year in hopes of making the drug available to patients with small cell lung cancer.

The agent also has been evaluated for patients with triple-negative breast cancer.

Other agents in development include lerociclib, an oral CDK 4/6 inhibitor, and G1T48, an oral selective estrogen receptor degrader in development for patients with ER-positive breast cancer. – by Mark Leiser

CHICAGO — Raj Malik, MD, chief medical officer and senior vice president for research and development at G1 Therapeutics, spoke with HemOnc Today at ASCO Annual Meeting about study results the company presented and the investigational agents in the pipeline.

Malik provided an overview of research into trilaciclib, a cyclin dependent kinase (CDK) 4/6 inhibitor designed to protect patients’ bone marrow from the effects of chemotherapy.

Results showed patients treated with trilaciclib had significantly less incidence and duration of severe neutropenia. They also were less likely to require red blood cell transfusions.

The company expects to file for potential regulatory approval next year in hopes of making the drug available to patients with small cell lung cancer.

The agent also has been evaluated for patients with triple-negative breast cancer.

Other agents in development include lerociclib, an oral CDK 4/6 inhibitor, and G1T48, an oral selective estrogen receptor degrader in development for patients with ER-positive breast cancer. – by Mark Leiser

    See more from ASCO Annual Meeting